Claim 11, line 2 and Claim 13, line 1 please remove the underlining from the word "Nilutamide".

IN THE SPECIFICATION

Page 1, line 4 insert as a title - {METHOD OF DECREASING ATHEROSCLEROSIS AND ITS COMPLICATIONS}

a1

Page 1, line 4, after the aforesaid newly added title insert - {CROSS-REFERENCES TO RELATED APPLICATIONS - }.

a2

where? Page 1, line 7 insert as a paragraph - {There are no rights to inventions made under federally-sponsored research and development. The present invention was made entirely using private funds.}

a3

a4 where? NE Page 2, above line 1 insert as a title - - FIELD OF THE INVENTION - -.

a5 NE Page 2, line 15 insert as a title - - DESCRIPTION OF RELATED PRIOR ART - -.

a6 NE Page 4, line 5 insert as a title - - SUMMARY OF THE INVENTION AND DESCRIPTION OF PREFERRED EMBODIMENT - -.

IN THE ABSTRACT

Line 4, after "substance" insert - {such as Bicalutamide or Flutamide or Nilutamide -}.

REMARKS

The Examiners are thanked for the constructive interview afforded to the applicant and the undersigned attorney on October 13, 1999.

BACKGROUND OF THE INVENTION

There are many steps in the biosynthesis and utilization by the tissues of testosterone. Testosterone is made mostly in the testicles. A lesser amount is made in the adrenals. Production is stimulated by secretion of Gn RH or LHRH by the brain, which causes secretion of luteinizing hormone (LH) by the pituitary, which causes the testicles to make testosterone. Testosterone then flows into the blood stream and is absorbed by the target cells. Here it binds to a receptor and is transported into the cell and converted to dihydrotestosterone. This is bound and carried to the nucleus of the cell where it redirects cellular activity by turning on and off DNA. Hormonal manipulation is a term which refers to the reduction of testosterone or its effects by blocking any step in the above process in order to gain a desired effect. Until now the uses of hormonal manipulation include for example treating prostatic carcinoma, and treatment for baldness.

The present invention involves the use of hormonal manipulations in the prevention and treatment of atherosclerosis, coronary heart disease, stroke and peripheral vascular disease.

Leuprolide acetate is a synthetic nonapeptide of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH), the chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate salt sold under the trade name Lupron or Lupron Depot, as identified by US patent no. 4,897,256, the entire disclosure is incorporated by

Bicalutamide, a non-steroidal antiandrogen, chemical name is propanamide, N-(4 cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-(+-) sold under the trade name Casodex, as identified by US patent no. 4,636,505, the entire disclosure is incorporated by reference herein, is known for use in treatment of prostatic carcinoma.

a 6 A retrospective study was performed which compared the rates of patient reported heart attack in several groups: 1 - control group of males entering the urology office for any routine complaint. 2 - a group of prostate cancer patients treated with Leuprolide acetate, a LHRH inhibitor. 3 - a group of prostate cancer patients treated with Goserelin acetate (Zoladex), a LHRH inhibitor. 4 - a group of prostate cancer patients not treated with hormonal manipulation (neither Leuprolide or Goserelin). 5 - a group of patients treated with Finasteride (another form of hormonal manipulation). 6 - all patients on LHRH inhibitors (group 2 + group 3).

Ins B3 The patients on either ~~Leuprolide or Goserelin~~ were treated with the recommended doses indicated for the treatment of prostatic carcinoma, at either one or three month intervals depending on the preparation used. Leuprolide was dosed at 7.5 mg monthly (single intramuscular injection) or at 22.5 mg at 3 month intervals (single intramuscular injection). Goserelin was dosed at 3.6 mg monthly (subcutaneous injection) or at a dose of 10.8 mg at 3 month intervals (subcutaneous injection).